DDEL-01. ANIMAL STUDIES WITH A NEW CNS DRUG DELIVERY DEVICE TO EFFECTIVELY TREAT LEPTOMENINGEAL CARCINOMATOSIS PATIENTS

Abstract Background Appropriate drug distribution is needed for effective treatment of brain metastases and leptomeningeal carcinomatosis. Lack proper bioavailability in the CNS contributes to poor outcome these patients. EnClear Therapies has developed a device delivering intrathecal therapeutics utilizing active control CSF flow through an external pump. Herein, we look at delivery methotrexate with EnClear’s system its impact concentration sheep non-human primates. METHODS The utilizes two implantable catheters (intracranial ventricular lumbar thecal sac) extracorporeal pump that controls speed direction flow. Software monitors output from sensor arrays pressure, respiration, heart rate. Gadolinium MRI were used determine characteristics. Administration Methotrexate via was compared current standards delivery, intracerebroventricular or administration. levels measured Liquid Chromatography/Mass Spectrometry CSF, blood, multiple peripheral tissues. RESULTS There two-fold increase regions including deeper structures striatum using EnClear's system, traditional delivery. Higher peak reached use simultaneous reduction nerves systemic tissues – potential source toxicity. Conclusions In large animal studies, first time, demonstrated increased parenchymal addition parenchyma, this novel shown improved throughout leptomeninges as decreased distribution.